Phase II study of intravenous Doxil in malignant pleural mesothelioma.

Abstract

Twenty-four patients with pleural mesothelioma received 50 mg/m2 of Doxil every four weeks. At follow-up, the disease had stabilized in 43% percent of patients and had progressed in 57%. No objective responses were observed. Estimated median survival of all patients was 37 weeks. Major toxicities were erythrodysesthesia of hands and feet and myelosuppression. No cardiac toxicity was observed. We concluded that Doxil at this dosage and schedule is inactive against pleural mesothelioma.

• Authors: Y Oh, R Perez-Soler, F V Fossella, B S Glisson, J Kurie, G L Walsh, M Truong, D M Shin
• Journal: Investigational new drugs (Invest New Drugs) Vol. 18 Issue 3 Pg. 243-5 (Aug 2000) ISSN: 0167-6997 [Print] United States
• PMID: 10958592 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Doxorubicin

Topics

• Aged
• Antibiotics, Antineoplastic (therapeutic use)
• Doxorubicin (administration & dosage, adverse effects, therapeutic use)
• Female
• Humans
• Infusions, Intravenous
• Male
• Mesothelioma (drug therapy)
• Middle Aged
• Pleural Neoplasms (drug therapy)